Back to Pennsylvania

HR220 • 2025

A Resolution designating the week of May 4 through 10, 2025, as "Tardive Dyskinesia Awareness Week" in Pennsylvania.

A Resolution designating the week of May 4 through 10, 2025, as "Tardive Dyskinesia Awareness Week" in Pennsylvania.

Passed Legislature

This bill passed both chambers and reached final enrollment, even if later executive action is not shown here.

Sponsor
DELLOSO
Last action
2025-05-01
Official status
Referred to HUMAN SERVICES, May 1, 2025
Effective date
Not listed

Plain English Breakdown

Using official source text because the generated explanation was unavailable or could not be confirmed against the official bill text.

A Resolution designating the week of May 4 through 10, 2025, as "Tardive Dyskinesia Awareness Week" in Pennsylvania.

A Resolution designating the week of May 4 through 10, 2025, as "Tardive Dyskinesia Awareness Week" in Pennsylvania.

What This Bill Does

  • A Resolution designating the week of May 4 through 10, 2025, as "Tardive Dyskinesia Awareness Week" in Pennsylvania.

Limits and Unknowns

  • This entry is temporarily using official source text because the generated explanation could not be confirmed against the official bill text during the last sync.

Bill History

  1. 2025-05-01 HUMAN SERVICES

    Referred to HUMAN SERVICES, May 1, 2025

Official Summary Text

A Resolution designating the week of May 4 through 10, 2025, as "Tardive Dyskinesia Awareness Week" in Pennsylvania.

Current Bill Text

Read the full stored bill text
PRINTER'S NO. 1564
THE GENERAL ASSEMBLY OF PENNSYLVANIA
HOUSE RESOLUTION
No. 220
Session of
2025
INTRODUCED BY DELLOSO, WAXMAN, SCHLOSSBERG, VENKAT, HILL-EVANS,
KAZEEM, PROBST, SANCHEZ AND NEILSON, APRIL 30, 2025
REFERRED TO COMMITTEE ON HUMAN SERVICES, MAY 1, 2025
A RESOLUTION
Designating the week of May 4 through 10, 2025, as "Tardive
Dyskinesia Awareness Week" in Pennsylvania.
WHEREAS, Many people with serious mental health conditions,
such as bipolar disorder, major depressive disorder,
schizophrenia and schizoaffective disorder, or with
gastrointestinal disorders, including gastroparesis, upset
stomach, nausea and vomiting, may be treated with medications
that work as dopamine receptor blocking agents (DRBAs),
including antipsychotics and antiemetics; and
WHEREAS, While ongoing treatment with these medications can
be necessary, prolonged use is associated with tardive
dyskinesia (TD), an involuntary movement disorder that is
characterized by uncontrollable, abnormal and repetitive
movements of the face, torso, limbs, fingers or toes; and
WHEREAS, Even mild symptoms of TD can impact people
physically, socially and emotionally; and
WHEREAS, It is estimated that TD affects approximately
800,000 people in the United States and approximately 60% of
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
people with TD have not been diagnosed, making it important to
raise awareness about the symptoms; and
WHEREAS, It is important that people taking DRBA medication
be monitored for TD by a health care provider; and
WHEREAS, The American Psychiatric Association recommends
regular screenings for TD; and
WHEREAS, Clinical research has led to approval of treatments
for adults with TD by the United States Food and Drug
Administration; and
WHEREAS, Recognition and treatment of TD can make a positive
impact in the lives of many people experiencing psychotic and
mood disorders; and
WHEREAS, The House of Representatives wants to raise
awareness of TD among the public and medical community;
therefore be it
RESOLVED, That the House of Representatives designate the
week of May 4 through 10, 2025, as "Tardive Dyskinesia Awareness
Week" in Pennsylvania; and be it further
RESOLVED, That the House of Representatives encourage people
in this Commonwealth and across the United States to become
better informed about and aware of tardive dyskinesia.
20250HR0220PN1564 - 2 -
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21